Website traffic
How much traffic does skyrizi.com get?
450.72K
+14.14%MoMEstimated monthly visits
486.78K324.52K162.26K0
Global rank
132,104
Country rank · United States
27,535
Category rank · Pharmacy
52
Average visit duration
00:47
Pages per visit
1.47
Bounce rate
75.81%
Domain age
9.7 years
Search share
9.0%
Sources
Where does skyrizi.com's traffic come from?
- Paid search32.1%
- Display ads30.1%
- Direct24.8%
- Search9.0%
- Email1.7%
- Social1.2%
- Referrals0.9%
- Generative AI0.2%
- Other0.1%
Regions
Which countries visit skyrizi.com?
- United States93.5%
- Canada1.3%
- United Kingdom1.3%
- Australia0.8%
- India0.5%
See how skyrizi.com compares with the most visited websites in the world, the fastest growing websites and sites gaining organic search traffic.
Search visibility
What keywords send traffic to skyrizi.com?
Keyword samples
Estimated visitsMonthly searchesVisits ÷ searches
- skyriziBRAND5.22K32.77K16%
- skyrizi copay cardBRAND1.05K1.09K96%
- bexarotene1.01K1.05K96%
- ulcerative colitis84093.8K1%
- skyrizi copay assistanceBRAND79093085%
Keyword rankings
Keyword rankings
86.4M
Search estimate
New 1 · Up 2
- Ranking keywords
- 12,400
- Landing pages
- 4
- Search competitors
- 4
- AI citations
- 2
PositionEstimated visits
- google#142M
- gmail#118.2M
- google maps#19.4M
- google drive#14.1M
Full keyword rankings are a Pro feature
Unlock ProSite profile
What does skyrizi.com show publicly?
- HTTP 200
- Email authentication
- Hosting ASN
- HTTP
- 200
- Page size
- 207.6 KiB
- Hosting
- ABBVIE · AS62763
- Email authentication
- SPF · DMARC reject
- TLS
- TLSv1.2 · 145 days
Page and SEO
- Final URL
- https://www.skyrizi.com/
- Title
- SKYRIZI® (risankizumab‐rzaa): A Biologic for Ps, PsA, CD, & UC
- Description
- Get to know SKYRIZI, an FDA‐approved biologic treatment for adults and children with Ps & PsA and adults with CD & UC. See full Safety and Prescribing Information.
- Cross-origin redirect
- Yes
- Word count
- 5,109
- Internal / external links
- 12 / 20
- Canonical
- https://www.skyrizi.com/
- Language
- en-US
- H1 / H2
- 2 / 4
- Images missing alt
- 3 / 10
- OG / Twitter
- OG · Twitter
Technology and tracking2 technologies
- Technology clues
- React · Bot protection
- External script hosts
- rum.hlx.page · assets.adobedtm.com
- Security headers
- 3 / 6
- HSTS / CSP
- HSTS
- Cookie
- 2（Secure 1）
Email and DNS securitySet
- SPF
- Set
- DMARC
- Set · reject
- DKIM selectors
- Not found
- IPv6
- No AAAA
- Site verification TXT
- Facebook · Google
- SOA
- ns1.abbviedns.com
- NS
- ns1.abbviedns.com. · ns2.abbviedns.com. · ns3.abbviedns.com. · 1 more
Hosting and networkAS62763
- A
- 159.180.132.176
- Hosting ASN
- AS62763 · 159.180.132.0/22
- Hosting organization
- ABBVIE - AbbVie, Inc.
- Hosting country
- GB
- BGP announcement
- Yes
- TLS
- TLSv1.2 · Verified
- Certificate issuer
- DigiCert Global G2 TLS RSA SHA256 2020 CA1
- Certificate remaining
- 145 days
- Certificate SAN
- DNS:humira.com · DNS:abbvieaccess.com · DNS:abbviecfcommitment.com · DNS:abbvieeyecare.com · 16 more
robots and AI crawlingHTTP 200
- Robots.txt
- 200
- Global Disallow /
- No
- Sitemap
- Index · 6
- AI explicitly disallowed
- 0
- AI explicitly allowed
- 0
Well-known public paths
- Present / checked
- 0 / 5
Website information
When was skyrizi.com registered?
- Domain
- skyrizi.com
- Registration status
- Domain registered
- Registered
- 2017-02-02
- Registrar
- MarkMonitor Inc.
- Expires
- 2027-02-02
- Domain age
- 9.7 years
- DNSSEC
- No
- Registry status
- client delete prohibited · client transfer prohibited · client update prohibited
Similar sites
What sites are similar to skyrizi.com?
Website reports in the same category, with nearby monthly visits.
What's in this report
The report starts with a whole-site monthly visit estimate. Search visibility and public site facts follow when they exist.
- Website traffic is a modeled whole-site estimate, with a source, observation period and confidence.
- Search visibility is ranking keywords and search traffic, listed separately from whole-site visits.
- Missing or partial values stay marked in the report.